Thinprep®-processed fine-needle samples of breast are effective material for RNA- and DNA-based molecular diagnosis: Application to p53 mutation analysis

Cancer

Volumn 99, Issue 4, 2003, Pages 223-232

  Tisserand, Pascaline ^a   Fouquet, Coralie ^a   Marck, Véronique ^a   Mallard, Christine ^a   Fabre, Monique ^b   Vielh, Philippe ^a   Soussi, Thierry ^a,c  

^a INSTITUT CURIE   (France)

^b BICÊTRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Cellular banking; Cytology; Fine needle sampling; Immunocytochemistry; Molecular diagnosis; P53 tumor suppressor gene; ThinPrep

Indexed keywords

DNA; PROTEIN P53; RNA;

ARTICLE; ASPIRATION CYTOLOGY; BREAST CANCER; BREAST DISEASE; CANCER CELL CULTURE; CANCER CYTODIAGNOSIS; CELL STRAIN MCF 7; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CARCINOMA; CELL CULTURE; EVALUATION; FEMALE; GENETICS; HEALTH CARE FACILITY; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; METHODOLOGY; MICROTOMY; NEEDLE BIOPSY; NUCLEOTIDE SEQUENCE; PATHOLOGY; SENSITIVITY AND SPECIFICITY; TIME;

BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MICROTOMY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SPECIMEN HANDLING; TIME FACTORS; TISSUE BANKS; TUMOR CELLS, CULTURED;

EID: 0041471260     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11258     Document Type: Article

References (20)

1. Cotton RG. Mutation detection 2001: novel technologies, developments and applications for analysis of the human genome. Hum Mutat. 2002;19:313-314.
2. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002;3:285-298.
3. Nasuti JF, Gupta PK, Baloch ZW. Diagnostic value and cost-effectiveness of on-site evaluation of fine-needle aspiration specimens: review of 5,688 cases. Diagn Cytopathol. 2002; 27:1-4.
4. Bedard YC, Pollett AF. Breast fine-needle aspiration. A comparison of ThinPrep and conventional smears. Am J Clin Pathol. 1999;111:523-527.
5. Li SQ, O'Leary TJ, Sobin LH, Erozan YS, Rosenthal DL, Przygodzki RM. Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumors. Acta Cytol. 2000;44:981-986.
6. Ball HM, Hupp TR, Ziyaie D, Purdie CA, Kernohan NM, Thompson AM. Differential p53 protein expression in breast cancer fine needle aspirates: the potential for in vivo monitoring. Br J Cancer. 2001;85:1102-1105.
7. Lavarino C, Corletto V, Mezzelani A, et al. Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma. Br J Cancer. 1998;77: 125-130.
8. Pollett A, Bedard YC, Li SQ, Rohan T, Kandel R. Correlation of p53 mutations in ThinPrep-processed fine needle breast aspirates with surgically resected breast cancers. Mod Pathol. 2000;13:1173-1179.
9. Vielh P, Magdelenat H, Mosseri V, Remvikos Y, di Bonito L. Immunocytochemical determination of estrogen and progesterone receptors on 50 fine-needle samples of breast cancer. A prospective study including biochemical correlation and DNA flow cytometric analysis. Am J Clin Pathol. 1992;97:254-261.
10. Zajdela A, Zillhardt P, Voillemot N. Cytological diagnosis by fine needle sampling without aspiration. Cancer. 1987;59: 1201-1205.
11. Flaman JM, Frebourg T, Moreau V, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA. 1995;92:3963-3967.
12. Waridel F, Estreicher A, Bron L, et al. Field cancerisation and polyclonal p53 mutation in the upper aerodigestive tract. Oncogene. 1997;14:163-169.
13. de Cremoux P, Salomon AV, Liva S, et al. p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst. 1999;91:641-643.
14. Dillon DA, Hipolito E, Zheng K, Rimm DL, Costa JC. p53 mutations as tumor markers in fine needle aspirates of palpable breast masses. Acta Cytol. 2002;46:841-847.
15. Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer. 2002;94:2199-2210.
16. Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab. 2001;86:2187-2190.
17. Pinto MM, Emanuel JR, Chaturvedi V, Costa J. Ki-ras mutations and the carcinoembryonic antigen level in fine needle aspirates of the pancreas. Acta Cytol. 1997;41:427-434.
18. Dimulescu II, Unger ER, Lee DR, Reeves WC, Vernon SD. Characterization of RNA in cytologic samples preserved in a methanol-based collection solution. Mol Diagn. 1998;3:67-71.
19. Ellis M, Davis N, Coop A, et al. Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res. 2002;8: 1155-1166.
20. Sotiriou C, Powles T, Dowsett M, et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002;4:R3.